ASCO 2026: Interim data released for upcoming BRAF and RAS mCRC therapies

"ASCO 2026: Interim data released for upcoming BRAF and RAS mCRC therapies" was originally created and published by Clinical ...
Morning Overview on MSN

Daraxonrasib just doubled how long patients with advanced pancreatic cancer live — 13.2 months on the new pill versus 6.6 months on chemotherapy in a 500-patient trial

Patients with previously treated metastatic pancreatic cancer survived a median of 13.2 months on the oral drug daraxonrasib, ...
ascopubs.org

A phase II, single-arm, open-label clinical trial to evaluate the combination of cadonilimab injection and gut microbiota modulation in the treatment of persistent, recurrent ...

ANA trial: Development of a diagnostic test and dynamic evaluation of ctDNA to optimize follow-up and tailor treatment in patients with HPV-related cervical and anal tumors. Background: Current ...

Travere Therapeutics Presents Long-Term Open-Label Extension Data from the Phase 3 DUPLEX Study at the 63rd European Renal Association (ERA) 2026 Congress

Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced long-term results from the ongoing Phase 3 DUPLEX Study open-label extension (OLE) of FILSPARI® (sparsentan) in the treatment of focal ...
Nasdaq

Satellos Announces Encouraging Functional Data from the 28-day Phase 1b Open-Label Trial of SAT-3247 in Adults with Duchenne Muscular Dystrophy

Phase 1b data shows treatment with SAT-3247 was safe and well-tolerated Pharmacokinetic (PK) profile of SAT-3247 translated as expected to Duchenne Muscular Dystrophy (DMD) patients taking concurrent ...
The American Journal of Managed Care

Acoramidis Shows Durable Benefit at 54 Months in ATTR-CM

Open-label extension data from 389 ATTRibute-CM completers compared continuous acoramidis with placebo-to-acoramidis ...
GlobalData on MSN

Lilly reports positive interim results from Heart-2 trial of VERVE-102

The study involved 35 participants with heterozygous familial hypercholesterolaemia or premature coronary artery disease.
ascopubs.org

An open-label, phase I trial of the SIRPα monoclonal antibody, BI 770371, alone and in combination with the PD-1 inhibitor ezabenlimab in patients with advanced solid tumors.

Preliminary results from the dose-escalation stage of a phase I trial of an anti-CCR8 antibody in patients with relapsed/refractory cutaneous T-cell lymphoma (R/R CTCL). A novel application of deep ...
Nasdaq

Cassava Sciences Announces Expansion of Open-Label Extension Trials

Ongoing open-label extension trials of simufilam in Alzheimer’s disease to be extended by up to an additional 36 months. The extension provides participants the opportunity to continue on treatment, ...